Evidence map›Paper›PMID 39112504›Full record

ArticleBlood cancer journal2024

Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin.

Jayastu Senapati, Elias Jabbour, Nicholas J Short, Nitin Jain, Fadi Haddad, Tharakeswara Bathala, Iuliia Kovalenko, Aram Bidikian, Farhad Ravandi, Issa Khouri and 7 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. CD22 as a Target for Hematological Malignancies and Autoimmune Diseases.International journal of molecular sciences · 2026
    Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jayastu Senapati *Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-6831-2567
Elias Jabbour *Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. ejabbour@mdanderson.org.ORCID 0000-0003-4465-6119
Nicholas J ShortDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2983-2738
Nitin JainDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Fadi HaddadDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-9702-8485
Tharakeswara BathalaDepartment of Abdominal Imaging, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Iuliia KovalenkoDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4821-2195
Aram BidikianDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Farhad RavandiDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7621-377X
Issa KhouriDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Tapan M KadiaDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-9892-9832
Rebecca GarrisDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Guillermo Montalban BravoDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Kelly ChienDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth ShpallDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Partow KebriaeiDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Hagop M KantarjianDepartment of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-1908-3307

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Elasticity Imaging TechniquesHepatic Veno-Occlusive DiseaseInotuzumab OzogamicinPrecursor Cell Lymphoblastic Leukemia-LymphomaAdultAgedAntineoplastic Agents, ImmunologicalChemical and Drug Induced Liver InjuryFemaleHumansLiverMaleMiddle AgedRisk AssessmentRisk FactorsAntineoplastic Agents, ImmunologicalInotuzumab Ozogamicin

Identifiers

PMID39112504
PMCPMC11306742

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.